Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1 ‐expressing head and neck cancer
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Jeon Yeob Jang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immune Checkpoint Inhibitors, Tumor Microenvironment, Head and Neck Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute (KHIDI), National Research Foundation of Korea.
Abstract (Originalsprache)
Immune checkpoint blockers (ICBs) targeting programmed cell death protein 1 (PD‐1) have been proven to be an effective first‐line therapy against programmed cell death 1 ligand 1 ( PD‐L1 ; also known as CD274 molecule)‐expressing head and neck squamous cell carcinoma (HNSCC) in recent KEYNOTE‐048 trial. However, associated changes in the tumor microenvironment (TME) and underlying mechanisms remain elusive. Oral tumors in C57/BL6 mice were induced by administering 7,12‐dimethylbenzanthracene into the buccal mucosa. Single‐cell suspension was isolated from tumor tissue; proliferating cells were injected subcutaneously into the left flank of mice to establish Ajou oral cancer (AOC) cell lines. Subsequently, a syngeneic PD‐L1 ‐expressing HNSCC model was developed by injecting AOC cells into the buccal or tongue area. The model recapitulated human HNSCC molecular features and showed reliable in vivo tumorigenicity with significant PD‐L1 expression. ICB monotherapy induced global changes in the TME, including vascular normalization. Furthermore, the antitumor effect of ICB monotherapy was superior to those of other therapeutic agents, including cisplatin and inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2). The ICB‐induced antitumorigenicity and TME normalization were alleviated by blocking the type I interferon pathway. In summary, ICB monotherapy is sufficient to induce TME normalization in the syngeneic model; the type I interferon pathway is indispensable in realizing the effects of ICBs. Furthermore, these results explain the underlying mechanism of the efficacy of ICB monotherapy against PD‐L1 ‐expressing HNSCC in the KEYNOTE‐048 trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Ajou University School of Medicine, Suwon, Korea.
- Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.
- Department of Physiology, Ajou University School of Medicine, Suwon, Korea.
- Deparment of Molecular Science and Technology, Ajou University, Suwon, Korea.
ORCID-Profile: Jeon Yeob Jang, Bok-Soon Lee, Ji-Hye Choi, Hyun Goo Woo, Chul-Ho Kim
Förderung
- Korea Health Industry Development Institute (KHIDI)
- National Research Foundation of Korea
Zitieren
APA
Jang, J. Y., Lee, B. S., Huang, M., Seo, C., Choi, J. H., Shin, Y. S., Woo, H. G., & Kim, C. H. (2024). Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1 ‐expressing head and neck cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13633
Vancouver
Jang JY, Lee BS, Huang M, Seo C, Choi JH, Shin YS, et al. Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1 ‐expressing head and neck cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13633
BibTeX
@article{Jang2024,
author = {Jang, Jeon Yeob and Lee, Bok-Soon and Huang, Mei and Seo, Chorong and Choi, Ji-Hye and Shin, Yoo Seob and Woo, Hyun Goo and Kim, Chul-Ho},
title = {Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1 ‐expressing head and neck cancer},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13633}
}
EUVIMED